Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 43Lymphoma, Non-Hodgkin 24Lymphoma, Follicular 17Lymphoma 14Recurrence 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, B-Cell 9Neoplasms 5Lymphoma, B-Cell, Marginal Zone 4Melanoma 3Leukemia 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Leukemia, B-Cell 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Urinary Bladder Neoplasms 1Tumor Lysis Syndrome 1Solid Cancers 1Prostatic Neoplasms 1Part1: Advanced B-cell Malignancies 1Ovarian Neoplasms 1Oncology Patients Receiving Chemotherapy 1Neoplasm Metastasis 1Mesothelioma 1Mature B-cell Malignancies 1

Interventions

Rituximab 8dacetuzumab 5blinatumomab 5ibrutinib 3Cyclophosphamide 3tetulomab tetraxetan lu-177 2ponatinib 2cobomarsen 2acalabrutinib 2Vincristine 2Prednisone 2Lutetium 2Ifosfamide 2Everolimus 2Etoposide 2Doxorubicin 2Carboplatin 2venetoclax 1sepantronium 1pomalidomide 1obinutuzumab 1fludarabine 1ficlatuzumab 1enzalutamide 1durvalumab 1denileukin diftitox 1cirmtuzumab 1amonafide 1Vorinostat 1Tinzaparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphatic Diseases × obinutuzumab × Clear all
NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡